Search Our Site

News filed in:

"Press Release"

2018 Specialty Drug Trends

By: Jason Marcewicz  |  Content and Communications Specialist | Advanced Medical Strategies 2018 Specialty Drug Trends • 44 specialty drug approvals in 2018 • 59 total FDA–approved novel drugs in 2018 • Branded specialty drugs account for roughly 1-3% of branded drug prescriptions filled, but compriseapproximately 30% of total branded drug spending • Specialty drug... Read More »

Read More →

By: Jason Marcewicz  |  Content and Communications Specialist | Advanced Medical Strategies 2018 Specialty Drug Trends • 44 specialty drug approvals in 2018 • 59 total FDA–approved novel drugs in 2018 • Branded specialty drugs account for roughly 1-3% of branded drug prescriptions filled, but compriseapproximately 30% of total branded drug spending • Specialty drug… Read More »

[...]

Read More

2018 Top 5 Lists

By Jason Marcewicz | Content and Communications Specialist | Advanced Medical Strategies AMS has released its fifth annual top five list of researched specialty drugs and diagnoses this year’s list includes: 2018 Top 5 PredictRx Views 2018 Top 5 PredictDx Views 2017-18 Top 5 Increased PredictRx Views 2017-18 Top 5 Increased PredictDx Views As with... Read More »

Read More →

By Jason Marcewicz | Content and Communications Specialist | Advanced Medical Strategies AMS has released its fifth annual top five list of researched specialty drugs and diagnoses this year’s list includes: 2018 Top 5 PredictRx Views 2018 Top 5 PredictDx Views 2017-18 Top 5 Increased PredictRx Views 2017-18 Top 5 Increased PredictDx Views As with… Read More »

[...]

Read More

Dr. Stacy’s Curbside Consult

  U.S. women are less likely than men to get statins after heart attack. That discrepancy may explain why death rates for women are higher.

Read More →

  U.S. women are less likely than men to get statins after heart attack. That discrepancy may explain why death rates for women are higher.

[...]

Read More

Insys Update: Stunning Numbers, Devastating Results

By: Jason Marcewicz  |  Content and Communications Specialist | Advanced Medical Strategies The pharmaceutical company Insys Therapeutics has been in the news a lot recently—and for all the wrong reasons. Last September AMS reported about Insys’ schemes to sell more of their pain drug Subsys to unwitting physicians. Now, it seems that Insys didn’t just... Read More »

Read More →

By: Jason Marcewicz  |  Content and Communications Specialist | Advanced Medical Strategies The pharmaceutical company Insys Therapeutics has been in the news a lot recently—and for all the wrong reasons. Last September AMS reported about Insys’ schemes to sell more of their pain drug Subsys to unwitting physicians. Now, it seems that Insys didn’t just… Read More »

[...]

Read More

By: Jason Marcewicz  |  Content and Communications Specialist | Advanced Medical Strategies Spinal cord stimulation (SCS) is a pain-relief technique that continuously delivers a low-voltage electrical current to the spinal cord to block the sensation of pain. SCS is the most commonly used implantable neurostimulation technology for management of pain syndromes. As many as 50,000… Read More »

[...]

Read More

By: Jason Marcewicz  |  Content and Communications Specialist | Advanced Medical Strategies Specialty drugs continue to outpace traditional brand-name pharmaceuticals and generics, both in percentage of growth and absolute costs. In 1990 there were 10 specialty drugs on the market. By the mid-1990s, about 30. In 2015, 300. That year the average annual price of… Read More »

[...]

Read More

Advanced Medical Strategies (AMS) is pleased to release our 4th annual Top 5 list of the most commonly researched specialty drugs of 2017.   For the PredictRx Top 5 Researched Drugs of 2017, Remicade again tops the list as the one AMS clients inquired about the most during the past 12 months. Industry professionals should… Read More »

[...]

Read More

Advanced Medical Strategies Makes Inc. 5000 List of America’s Fastest-Growing Companies

LYNNFIELD, Mass — August 21, 2017— Advanced Medical Strategies (AMS), an industry leader in delivering technology-driven solutions for payment integrity, risk management, and high dollar claims issues, is proud to announce that it has been officially recognized by Inc. as one of America’s fasting growing private companies. The annual Inc. 5000 is ranked according to... Read More »

Read More →

LYNNFIELD, Mass — August 21, 2017— Advanced Medical Strategies (AMS), an industry leader in delivering technology-driven solutions for payment integrity, risk management, and high dollar claims issues, is proud to announce that it has been officially recognized by Inc. as one of America’s fasting growing private companies. The annual Inc. 5000 is ranked according to… Read More »

[...]

Read More

Biogen’s Regulatory Applications for Nusinersen as a Treatment for Spinal Muscular Atrophy Accepted by FDA and EMA

Biogen (NASDAQ: BIIB) today announced that its New Drug Application (NDA) for nusinersen, an investigational treatment for spinal muscular atrophy (SMA), has been accepted by the U.S. Food and Drug Administration (FDA) for Priority Review, and that the company’s Marketing Authorization Application (MAA) has been validated by the European Medicines Agency (EMA). Nusinersen had previously... Read More »

Read More →

Biogen (NASDAQ: BIIB) today announced that its New Drug Application (NDA) for nusinersen, an investigational treatment for spinal muscular atrophy (SMA), has been accepted by the U.S. Food and Drug Administration (FDA) for Priority Review, and that the company’s Marketing Authorization Application (MAA) has been validated by the European Medicines Agency (EMA). Nusinersen had previously… Read More »

[...]

Read More

FDA approves brain implant to help reduce Parkinson’s disease and essential tremor symptoms

Originally posted on: FDA.gov The U.S. Food and Drug Administration today approved the Brio Neurostimulation System, an implantable deep brain stimulation device to help reduce the symptoms of Parkinson’s disease and essential tremor, a movement disorder that is one of the most common causes of tremors. The Brio Neurostimulation System can help some patients when... Read More »

Read More →

Originally posted on: FDA.gov The U.S. Food and Drug Administration today approved the Brio Neurostimulation System, an implantable deep brain stimulation device to help reduce the symptoms of Parkinson’s disease and essential tremor, a movement disorder that is one of the most common causes of tremors. The Brio Neurostimulation System can help some patients when… Read More »

[...]

Read More

Page 1 of 2

Categories
Archives